

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	ARATHOON ET AL.	Examiner:	A. HOLLERAN
Serial No.:	09/520,130	Group Art Unit:	1643
Filed:	MARCH 7, 2000	Docket No.:	11669.132USC1
Confirmation No.:	1353	Customer No.:	23552
Title:	A METHOD FOR MAKING MULTISPECIFIC ANTIBODIES HAVING HETEROMULTIMERIC AND COMMON COMPONENTS		

---

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**(37 C.F.R. § 1.97(b))**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Please charge Deposit Account No. 13-2725 for consideration of the items listed on the enclosed Form 1449.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. § 1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date: December 14, 2006

Katherine M. Kowalchuk  
Katherine M. Kowalchuk  
Reg. No. 36,848



<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 11669.132USC1	Application Number: 09/520,130
	Applicant: ARATHOON ET AL.	
	Filing Date: 03/07/2000	Group Art Unit: 1643
	Customer No. 23552	Confirmation No.: 1353

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,515,110 B1	02/04/2003	WHITLOW ET AL.			

  

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

  

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Barton, "Protein sequence alignment and database scanning", <u>Protein Structure Prediction</u> , pps. 31-63 (1996)
	de Kruif et al., "Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions", <u>J. Mol. Biol.</u> , 248:97-105 (1995)
	Eck et al., "Gene-Based Therapy", In: <u>The Pharmacological Basis of Therapeutics</u> , Goodman and Gilman, Eds, Chap. 5, pp. 77-101 (1996)
	George et al., "Current Methods in Sequence Comparison and Analysis", <u>Macromolecular Sequencing and Synthesis</u> , pps. 127-149 (1988)
	Houdebine et al., "Production of pharmaceutical proteins from transgenic animals", <u>Journal of Biotechnology</u> , 34:269-287 (1994)
	Verma et al., "Gene therapy - promises, problems and prospects", <u>Nature</u> , 389:239-242 (1997)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	